Literature DB >> 477312

Blood levels of medroxyprogesterone acetate after multiple injections of depoprovera or cycloprovera.

S Koetsawang, K Shrimanker, K Fotherby.   

Abstract

Mean levels of MPA in blood taken 90 days after injection were not significantly different between women who had received a single injection of DepoPrevera and those who had received eight injections at 90-day intervals. There was a wide variation in plasma MPA concentration in the two groups of women. In women who had received 31 to 45 injections of CycloProvera, plasma levels of MPA 28 days after injection were significantly higher than those of women who had received a single injection. The levels were also higher than those found in women 90 days after injection of DepoProvera. The results suggest that the dose of MPA in CycloProvera could be reduced.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 477312     DOI: 10.1016/0010-7824(79)90038-6

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

1.  Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.

Authors:  Anitra Beasley; Katharine O'Connell White; Serge Cremers; Carolyn Westhoff
Journal:  Contraception       Date:  2014-02-07       Impact factor: 3.375

Review 2.  Injectable contraception with depot medroxyprogesterone acetate. Current status.

Authors:  Andrew M Kaunitz; Allan Rosenfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females.

Authors:  Andrea E Bonny; Hannah L H Lange; Lynette K Rogers; Dave M Gothard; Michael D Reed
Journal:  Contraception       Date:  2014-02-01       Impact factor: 3.375

Review 4.  Long acting contraceptives. Present status.

Authors:  G Benagiano; F M Primiero
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

Review 5.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

6.  Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.

Authors:  Kavita Nanda; Rebecca Callahan; Douglas Taylor; Meng Wang; Kawango Agot; David Jenkins; Lut Van Damme; Laneta Dorflinger
Journal:  Contraception       Date:  2016-03-10       Impact factor: 3.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.